Organizing Chemotherapy and Hormonal Therapy: The Key Role of Supportive Agents

Last Modified: July 6, 2003

Share article


Conference Dates: February 5-6, 2004
Conference Location: Geneva, Switzerland


Sponsoring Group: MSKCC, Clinique de Genolier, Imedex

Conference Web Page URL: www.imedex.com/calendars/oncology.htm

Topics Covered: Conference Summary - Participants at this meeting will learn about new ways and means to optimize chemotherapy and hormonal therapy in cancer patients. Recent progress in antiemetic agents allows long term control of nausea and vomiting, not only acute phase control. New growth factors promise an easier erythropoietic and granulocytic support, and such support can be crucial for optimal outcomes. Bisphosphonates may have a role in adjuvant therapy, along with chemotherapy and hormonal agents. Decrease of mucositis and appropriate treatment of infectious complications in outpatients with solid tumours will also be discussed.

Registration Information: Online at www.imedex.com (registration will open in September),tel: +1 770-751-7332, fax: +1 770-751-7334, email: h.drew@imedex.com

Continuing Education: Yes


News
Hormone Receptor Levels Predict Trastuzumab Effect

Jan 4, 2012 - Patients with human epidermal growth factor receptor 2-positive advanced breast cancer whose tumors also express hormone receptors may be less responsive to the addition of trastuzumab to chemotherapy, suggesting that hormone receptor expression has a predictive role in determining response to therapy, according to research published in the Jan. 1 issue of Cancer.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More